| abstract |
The present invention relates to a bispecific single chain antibody comprising a first binding domain that immunospecifically binds to the T cell antigen CD3 and a second binding domain that immunospecifically binds to an EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTE”. The invention further relates to methods and compositions designed for the treatment, prevention, and / or management of disorders associated with abnormal expression and / or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancerous hyperproliferative cell disorders, and infections. The present invention further relates to a vector comprising a polynucleotide encoding EphA2-BiTE of the present invention, a host cell transformed with it, and its use for the production of said EphA2-BiTE. The present invention also provides a composition, such as a pharmaceutical composition, comprising any of the aforementioned EphA2-BiTEs, polynucleotides, or vectors alone or in combination with one or more prophylactic or therapeutic agents. . Also disclosed are screening methods for the EphA2-BiTE and kits comprising any of the aforementioned compositions and diagnostic reagents. |